holoxan pulver till injektions-/infusionsvätska, lösning
orifarm ab - ifosfamid - pulver till injektions-/infusionsvätska, lösning - ifosfamid 1 mg aktiv substans - ifosfamid
holoxan 40 mg/ml infusionsvätska, lösning
baxter medical ab - ifosfamid - infusionsvätska, lösning - 40 mg/ml - ifosfamid 40 mg aktiv substans - ifosfamid
holoxan pulver till injektions-/infusionsvätska, lösning
paranova läkemedel ab - ifosfamid - pulver till injektions-/infusionsvätska, lösning - ifosfamid 1 mg aktiv substans
holoxan pulver till injektions-/infusionsvätska, lösning
paranova läkemedel ab - ifosfamid - pulver till injektions-/infusionsvätska, lösning - ifosfamid 1 mg aktiv substans
cyclophosphamide accord 500 mg pulver till injektions-/infusionsvätska, lösning
accord healthcare b.v. - cyklofosfamidmonohydrat - pulver till injektions-/infusionsvätska, lösning - 500 mg - cyklofosfamidmonohydrat 534 mg aktiv substans; mannitol hjälpämne
cyclophosphamide accord 1000 mg pulver till injektions-/infusionsvätska, lösning
accord healthcare b.v. - cyklofosfamidmonohydrat - pulver till injektions-/infusionsvätska, lösning - 1000 mg - mannitol hjälpämne; cyklofosfamidmonohydrat 1069 mg aktiv substans
spevigo
boehringer ingelheim international gmbh - spesolimab - psoriasis - immunsuppressiva - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.
aubagio
sanofi winthrop industrie - teriflunomide - multipel skleros - selektiva immunsuppressiva medel - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).
teriflunomide mylan
mylan pharmaceuticals limited - teriflunomide - multipel skleros, skovvis förlöpande - immunsuppressiva - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).
teriflunomide accord
accord healthcare s.l.u. - teriflunomide - multipel skleros, skovvis förlöpande - immunsuppressiva, selektiva immunsuppressiva - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).